Manufacturer of golimumab publishes pregnancy safety data

Pregnancy safety data for golimumab have been published using global pharmacovigilance data collected by Janssen Pharmaceuticals. The authors of the publication concluded that rates of adverse pregnancy outcomes and major congenital anomalies in prospectively reported pregnancy cases were consistent with published background rates for the general population. More information can be found here.